Pharmacyclics Partnering 2009-2014, New Report Launched

This report provides all the information you require to better understand Pharmacyclics and its partnering interests and activities over the past five years.

Description

The Partnering Agreements with Pharmacyclics 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

This report provides all the information you require to better understand Pharmacyclics and its partnering interests and activities over the past five years.

On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

The initial chapters of this report provide an orientation of big biotech's dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big biotech companies based on 2013 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2009 to present date based on headline value.

Chapter 4 provides details on how to approach big biotech companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where big biotech companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negotiated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the user with the tools to make successful contact with the right partners effectively and efficiently.

Benefits

Partnering Agreements with Pharmacyclics report provides the user with the following key benefits:

• Detailed company profile of the company
• Partnering interests and therapy focus revealed
• Partnering activity since 2009 – number of deals per year
• Partnering activity for 2009-present
• Activity by deal type
• Activity by phase of development
• Activity by therapeutic area
• List of recent partner companies
• Detailed listing of all partnering deals since 2009
• Comprehensive access to actual contracts entered into by the company and its partners*
• Insight into the terms included in a partnering agreement
• Understand the key deal terms the company has agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Spanning over 100 pages, “Pharmacyclics Partnering 2009-2014” report covering the Introduction, Big biotech top 50 and dealmaking activity, Top Pharmacyclics deals by value, Submitting Opportunities to Prospective Partners, Forthcoming partnering events, Company Profile. The report covered 1 company – Pharmacyclics

Know more about this report at – http://mrr.cm/ZDM

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare